Indexed In
- Open J Gate
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Abstract
Prevalence of Viral Hepatitis C in Hemodialysis of the Casablanca-Settat Region
Failal I, Ezzaki S, Mtioui N, Khayat S, Zamed M, Medkouri G, Benghanem M, Ramdani B
Viral Hepatitis C remains the primary viral infection in chronic hemodialysis (HDC). It is a public health problem in this population because of its high prevalence firstly, and secondly, sound may become chronic and develop cirrhosis and hepatocellular carcinoma. The objective of this study was to evaluate the prevalence of viral Hepatitis C, determine the epidemiological factors related to the infection, and the proportion of patients.
Methods: This is a retrospective, descriptive, analytical and collaborative epidemiological, conducted among chronic hemodialysis patients in the region Casablanca-Settat. Operating a listing has been sent to all centers in the region.
Results: Of the 80 regional dialysis centers, 14 centers have responded favourably to our request, with a total of 1406 patients included. 34.28% of the liberal sector, 21.3% public and 44% of the association. The average age is 54.4 years (13-97 years) with a slight male predominance 52.2%. The prevalence of HCV antibody-positive 6.4%. In patients infected with HCV median duration of hemodialysis is 8 years. The most dominant genotypes are G1 in 47.3% and 49.1% in G2. The median duration of hemodialysis is 8 years. There is no significant difference between HCV+ patients and HVC patients for age, sex, transfusion and the number of blood units transfused. In addition, the median duration hemodialysis and the number of popular hemodialysis centers are significantly higher in the group of HCV+ patients (p<0.01). While no risk factors have been implicated in the infection with hepatitis B (p=NS). It should be noted that only 17 HCV+ patients were treated with HCV RNA undetectable after treatment.
Conclusion: The prevalence of HCV in hemodialysis is in gradual decline. The new direct-acting antivirals with the possibility of their support as well by mutual by hospitals can expect the eradication of viral hepatitis C in hemodialysis.
Published Date: 2020-01-22; Received Date: 2019-10-29